Mysterious Myeloma:
Emerging Therapies and CAR T-cell Therapy for Treatment of Multiple Myeloma
Series of Webinars on Multiple Myeloma (MM)
These insightful and informative webinars on the latest advancements in the treatment of multiple myeloma will bring together leading experts in the field and to start a discussion on cutting-edge therapies, clinical trials, and personalized treatment options for patients with myeloma. The webinars will provide valuable insights into the current landscape of myeloma care and the promising future of treatment options.
Learning objectives:
1. Evaluate Immunotherapy in Multiple Myeloma and the Challenges and Opportunities.
2. Understand the Mechanisms of Action (MOA) in Multiple Myeloma Immunotherapy.
3. Analyze the Role of Sequential Therapy in Multiple Myeloma Treatment.
4. Explore the Principles of Combination Therapy in Multiple Myeloma.
5. Assess the Current Landscape and Future of the MM Drug Market.
6. Review the current FDA-approved drugs and treatment regimens for Multiple Myeloma.
7. Predict the future direction of the MM drug market, considering factors such as new drug approvals, emerging therapies, and market trends. div block.
2. Understand the Mechanisms of Action (MOA) in Multiple Myeloma Immunotherapy.
3. Analyze the Role of Sequential Therapy in Multiple Myeloma Treatment.
4. Explore the Principles of Combination Therapy in Multiple Myeloma.
5. Assess the Current Landscape and Future of the MM Drug Market.
6. Review the current FDA-approved drugs and treatment regimens for Multiple Myeloma.
7. Predict the future direction of the MM drug market, considering factors such as new drug approvals, emerging therapies, and market trends. div block.
March 14th 2025, 2 - 3 PM ET
1 CE credit
Webinar 1: Immunotherapy in Multiple Myeloma
Join the discussion of several immunotherapeutic strategies for MM which have shown promising results in clinical trials, including monoclonal antibodies (mAbs), chimeric antigen receptor (CAR) T-cell therapy, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs) and, additionally, novel non-cellular therapies like CELMoDs, immunocytokines, immunotoxins, and NK-cell activators/engagers.
April, 2025
1 CE credit
Webinar 2: Biomarkers and CAR-T cell Therapies in Multiple Myeloma
Thank you for your interest in this educational program!
To visit the registration page please confirm that you are a Licensed Healthcare Professional
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
